List of Zoryve drug patents

Zoryve is owned by Arcutis.

Zoryve contains Roflumilast.

Zoryve has a total of 4 drug patents out of which 0 drug patents have expired.

Zoryve was authorised for market use on 29 July, 2022.

Zoryve is available in cream;topical dosage forms.

Zoryve can be used as topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. (1).

The generics of Zoryve are possible to be released after 25 August, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884050 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(14 years from now)

US9907788 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(14 years from now)

US10940142 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(14 years from now)

US11129818 ARCUTIS Topical roflumilast formulation having improved delivery and plasma half life
Aug, 2037

(14 years from now)

Do you want to check out ZORYVE patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Jul 29, 2025

Drugs and Companies using ROFLUMILAST ingredient

Market Authorisation Date: 29 July, 2022

Treatment: Topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. (1)

Dosage: CREAM;TOPICAL

More Information on Dosage

ZORYVE family patents

13

United States

3

China

2

Korea, Republic of

2

Brazil

2

Canada

2

Israel

2

Japan

2

Australia

2

European Union

EA

1

EA

1

Mexico

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic